SG10201503700WA - Modulation of splenocytes in cell therapy - Google Patents

Modulation of splenocytes in cell therapy

Info

Publication number
SG10201503700WA
SG10201503700WA SG10201503700WA SG10201503700WA SG10201503700WA SG 10201503700W A SG10201503700W A SG 10201503700WA SG 10201503700W A SG10201503700W A SG 10201503700WA SG 10201503700W A SG10201503700W A SG 10201503700WA SG 10201503700W A SG10201503700W A SG 10201503700WA
Authority
SG
Singapore
Prior art keywords
splenocytes
modulation
cell therapy
therapy
cell
Prior art date
Application number
SG10201503700WA
Inventor
W Mays Robert
Original Assignee
Abt Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Co filed Critical Abt Holding Co
Publication of SG10201503700WA publication Critical patent/SG10201503700WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG10201503700WA 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy SG10201503700WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33400110P 2010-05-12 2010-05-12
US201161440617P 2011-02-08 2011-02-08

Publications (1)

Publication Number Publication Date
SG10201503700WA true SG10201503700WA (en) 2015-06-29

Family

ID=44914707

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201913920PA SG10201913920PA (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy
SG2012083192A SG185526A1 (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy
SG10201503700WA SG10201503700WA (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201913920PA SG10201913920PA (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy
SG2012083192A SG185526A1 (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy

Country Status (8)

Country Link
US (3) US9937208B2 (en)
EP (1) EP2568991B3 (en)
AU (1) AU2016201524B2 (en)
CA (2) CA3128483A1 (en)
DK (1) DK2568991T6 (en)
IL (3) IL222942B (en)
SG (3) SG10201913920PA (en)
WO (1) WO2011143415A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
AU2009205886B2 (en) 2008-01-18 2015-08-27 Katholieke Universiteit Leuven Stem cell aggregates and methods for making and using
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
CA3128483A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
TWI687519B (en) 2012-12-06 2020-03-11 美商幹細胞生物科技股份有限公司 Lgr5+ somatic stem cells
KR102161726B1 (en) 2013-04-12 2020-10-06 사베리오 라프란체스카 Improving organs for transplantation
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
EP3220929A4 (en) * 2014-11-19 2018-06-27 Stembios Technologies, Inc. Somatic stem cells for treating bone defects
SG11201806245TA (en) 2016-01-21 2018-08-30 Abt Holding Co Stem cells for wound healing
JP2020512296A (en) * 2016-12-23 2020-04-23 ステムバイオス テクノロジーズ，インコーポレイテッド Use of somatic stem cells to reduce IL-6 levels
WO2021217098A1 (en) * 2020-04-23 2021-10-28 Abt Holding Company Treatment of virus-induced acute respiratory distress syndrome

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (en) 1986-02-13 1994-04-20 雪印乳業株式会社 Method and device for manufacturing capsule body
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US6436701B1 (en) 1988-09-21 2002-08-20 Babraham Institute Derivation of pluripotential embryonic cell lines from ungulate species
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
CA2123094C (en) 1991-11-06 1999-08-10 Paulo N. Correa Cell culture medium
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
FR2726003B1 (en) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9502022D0 (en) 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
WO1998059035A2 (en) 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
AU8401498A (en) 1997-07-14 1999-02-10 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999035243A2 (en) 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
AU755888B2 (en) 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
PT1066060E (en) 1998-04-03 2003-12-31 Osiris Therapeutics Inc MESENCHINEAL STAMINA CELLS AS IMMUNOSUPRESSORS
US6875607B1 (en) 1998-11-09 2005-04-05 Es Cell International Pte Ltd Embryonic stem cells
AU758073B2 (en) 1998-11-09 2003-03-13 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum free medium for chondrocyte-like cells
AU1341700A (en) 1998-11-13 2000-06-05 Osiris Therapeutics, Inc. Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050169896A1 (en) 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
IL147669A0 (en) 1999-07-29 2002-08-14 Baranowitz Steven Method for transdifferentiation of body tissues
ATE514772T1 (en) * 1999-08-05 2011-07-15 Abt Holding Co MULTIPOTENT ADULT STEM CELLS AND METHOD FOR ISOLATION THEREOF
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
WO2005113748A2 (en) 2004-04-21 2005-12-01 Regents Of The University Of Minnesota Mapc generation of lung tissue
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP1218487A2 (en) 1999-09-23 2002-07-03 Cell Science Therapeutics Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
ATE426016T1 (en) 1999-09-24 2009-04-15 Cybios Llc PLURIPOTENT EMBRYONAL STEM CELL-LIKE CELLS, COMPOSITIONS AND USES THEIR
US20030161817A1 (en) 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
WO2001021767A2 (en) 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US6866843B2 (en) 1999-12-06 2005-03-15 Viacell, Inc. Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
JP2003523767A (en) 2000-02-26 2003-08-12 アーテイセル・サイエンスイーズ・インコーポレイテツド Pluripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
EP2298867A3 (en) 2000-06-20 2013-01-16 ES Cell International Pte Ltd. Method of controlling differentiation of embryonic stem (ES) cells by culturing ES cells in the presence of bmp-2 pathway antagonists
EP1176189A1 (en) 2000-07-21 2002-01-30 Fornix Biosciences N.V. Stem cell-like cells
US20020098167A1 (en) 2000-07-31 2002-07-25 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
GB0026252D0 (en) 2000-10-26 2000-12-13 Univ Edinburgh Pluripotential stem cells
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
EP1349918B1 (en) 2000-12-06 2014-08-06 Anthrogenesis Corporation Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
IL157332A0 (en) 2001-02-14 2004-02-19 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
CA2856986C (en) 2001-02-14 2019-08-13 Anthrogenesis Corporation Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders
US7056738B2 (en) 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
KR100449141B1 (en) 2001-04-19 2004-09-21 (주)라이프코드 Method for differentiating a mesenchymal stem cell into neural cells
DK2105497T3 (en) 2001-04-24 2019-06-24 Dolores Baksh Progenitor cell populations, their expansion, and growth of non-hematopoietic cell types and tissues therefrom
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
BR0212098A (en) 2001-08-23 2004-08-03 Reliance Life Sciences Pvt Ltd Internal cell mass isolation method for the establishment of human embryonic stem cell lines (hesc)
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
JP2005512592A (en) * 2001-12-21 2005-05-12 マウント・シナイ・ホスピタル Cellular composition, method for producing cellular composition, and method of using cellular composition
US6703279B2 (en) 2002-01-04 2004-03-09 Promos Technologies, Inc. Semiconductor device having contact of Si-Ge combined with cobalt silicide
CA2473360A1 (en) 2002-01-25 2003-08-07 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
GB0221481D0 (en) 2002-09-16 2002-10-23 Richards John M Grip for hand held instruments
US20060228798A1 (en) 2002-11-27 2006-10-12 Catherine Verfaillie Homologous recombination in multipotent adult progenitor cells
AU2004227392A1 (en) 2003-04-04 2004-10-21 University Of Rochester Identification of novel nogo-receptors and methods related thereto
US20040235165A1 (en) 2003-05-19 2004-11-25 Darwin Prockop In vitro differentiation of adult stem cells
WO2005003317A2 (en) 2003-07-01 2005-01-13 Regents Of The University Of Minnesota Engineered blood vessels
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
ITRM20030376A1 (en) 2003-07-31 2005-02-01 Univ Roma PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA.
CN1845987A (en) 2003-08-29 2006-10-11 明尼苏达大学董事会 Kidney derived stem cells and methods for their isolation, differentiation and use
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
AU2004296848A1 (en) 2003-12-04 2005-06-23 Regents Of The University Of Minnesota Compositions and methods for the treatment of lysosomal storage disorders
EP1725656B1 (en) 2004-03-05 2013-10-02 John E. Davies Serum-free suspension culture system for mesenchymal progenitor cells
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298862B1 (en) 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
WO2006047593A2 (en) * 2004-10-22 2006-05-04 University Of South Florida Method of potentiating inflammatory and immune modulation for cell and drug therapy
WO2006047743A2 (en) 2004-10-26 2006-05-04 Regents Of The University Of Minnesota Swine multipotent adult progenitor cells
WO2006086639A1 (en) 2005-02-10 2006-08-17 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
AU2005331559B2 (en) 2005-05-05 2012-04-19 Regents Of The University Of Minnesota Use of NK cell inhibition to facilitate persistence of engrafted MHC-I negative cells
US20080311084A1 (en) 2005-05-05 2008-12-18 Verfaillie Catherine M Mapc Engraftment in the Hematopoietic System
WO2007016485A2 (en) 2005-07-29 2007-02-08 Athersys, Inc. Use of a gsk-3 inhibitor to maintain potency of cultured cells
WO2007117262A2 (en) 2005-07-29 2007-10-18 Athersys, Inc. Culture of non-embryonic cells at high cell density
JP2009511061A (en) 2005-10-14 2009-03-19 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Differentiation of non-embryonic stem cells into cells with pancreatic phenotype
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
CA3124132A1 (en) 2006-01-23 2007-08-02 Abt Holding Company Mapc therapeutics without adjunctive immunosuppressive treatment
WO2008020657A1 (en) * 2006-08-14 2008-02-21 Seoul National University Industry Foundation Acquired pluripotency through ovarian niche
AU2007321928A1 (en) 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
AU2009205886B2 (en) 2008-01-18 2015-08-27 Katholieke Universiteit Leuven Stem cell aggregates and methods for making and using
WO2009136283A2 (en) * 2008-05-08 2009-11-12 Coretherapix Slu Multipotent adult stem cell population
CN102202680A (en) 2008-09-04 2011-09-28 Abt控股公司 Use of stem cells to prevent neuronal dieback
US9057051B2 (en) 2008-10-31 2015-06-16 Katholieke Universiteit Leuven Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells
CN102625829B (en) 2009-07-21 2015-05-06 Abt控股公司 Use of stem cells to reduce leukocyte extravasation
US20110020292A1 (en) 2009-07-21 2011-01-27 Abt Holding Company Use of Stem Cells to Reduce Leukocyte Extravasation
US20130129686A1 (en) 2009-11-19 2013-05-23 Regents Of The University Reducing Inflammation Using Cell Therapy
WO2011106476A1 (en) 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
EP3940060A1 (en) * 2010-02-25 2022-01-19 ABT Holding Company Modulation of macrophage activation
US20110206647A1 (en) 2010-02-25 2011-08-25 Abt Holding Company Modulation of Angiogenesis
SG183498A1 (en) * 2010-02-25 2012-09-27 Abt Holding Co Modulation of angiogenesis
MX358007B (en) 2010-02-26 2018-08-02 Little Caesar Entpr Inc Automated pizza assembly system.
CA3128483A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US9090878B2 (en) 2010-06-17 2015-07-28 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
AU2011293440B2 (en) 2010-08-24 2016-05-05 Katholieke Universiteit Leuven Non-static suspension culture of cell aggregates
JP5364147B2 (en) 2011-01-17 2013-12-11 シナノケンシ株式会社 Magnet and method for manufacturing magnet
US9388388B2 (en) 2011-01-31 2016-07-12 Katholieke Universiteit Leuven Methods for making cells with an extra-embryonic endodermal precursor phenotype
SG10201604543PA (en) 2011-06-06 2016-07-28 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
KR102161726B1 (en) 2013-04-12 2020-10-06 사베리오 라프란체스카 Improving organs for transplantation
DK2992088T3 (en) 2013-04-30 2019-11-11 Univ Leuven Kath CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES
US20160069903A1 (en) * 2014-09-10 2016-03-10 Fundació Institute De Ciències Foròniques Method for detecting cells
US20160326494A1 (en) 2015-05-05 2016-11-10 Katholieke Universiteit Leuven Methods for Pancreatic Islet Transplantation
CA3012009A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
SG11201806245TA (en) 2016-01-21 2018-08-30 Abt Holding Co Stem cells for wound healing

Also Published As

Publication number Publication date
EP2568991B1 (en) 2018-03-21
AU2016201524B2 (en) 2017-06-08
US20180250342A1 (en) 2018-09-06
AU2011253014A1 (en) 2012-12-06
CA3128483A1 (en) 2011-11-17
IL274687A (en) 2020-06-30
DK2568991T6 (en) 2019-03-18
SG10201913920PA (en) 2020-03-30
WO2011143415A1 (en) 2011-11-17
CA2798895A1 (en) 2011-11-17
SG185526A1 (en) 2012-12-28
DK2568991T3 (en) 2018-06-18
US20110293642A1 (en) 2011-12-01
IL222942B (en) 2020-06-30
EP2568991A1 (en) 2013-03-20
IL222942A0 (en) 2012-12-31
IL274687B (en) 2021-09-30
AU2016201524A1 (en) 2016-03-24
US20200390821A1 (en) 2020-12-17
US10758570B2 (en) 2020-09-01
US9937208B2 (en) 2018-04-10
IL284501A (en) 2021-08-31
EP2568991A4 (en) 2013-11-06
EP2568991B3 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
IL284501A (en) Modulation of splenocytes in cell therapy
IL264271A (en) Methods of generating natural killer cells
HK1249548A1 (en) Aav -vectors for use in gene therapy of choroideremia
HK1211565A1 (en) Efficient treatment of wastewater using electrochemical cell
HK1190697A1 (en) Efficient treatment of wastewater using electrochemical cell
EP2621374A4 (en) Power assisted lipoplasty
EP2622713A4 (en) System and method to manage power usage
GB201100180D0 (en) Tumour cell and tissue culture
PL2659004T3 (en) Modulation of dynein in skin
IL220610A0 (en) Methods of rpoviding weight loss therapy in patients with major depression
EP2553089A4 (en) Cell therapy to improve wound healing and related compositions and methods
GB201005394D0 (en) Therapy
SG11201502214PA (en) Adipose tissue cells
EP2593113A4 (en) Cell therapy
TWM387549U (en) Solar energy massage slippers
GB201216933D0 (en) Adipose tissue cells
GB201216936D0 (en) Adipose tissue cells
AU2010900626A0 (en) Improvements in or Relating to Power Supplies
GB201007318D0 (en) Improvements in or relating to power adapters
GB201102232D0 (en) Inventions and therapy
GB201102216D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy
GB201102221D0 (en) Inventions and therapy
GB201102208D0 (en) Inventions and therapy